INO Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), c…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30. President and CEO Jacqueline Shea | ||
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP Inovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat. Shea described Inovio as a clinical-stage company d | ||
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... Inovio reports a narrowed net loss and strong progress toward a potential INO-3107 launch, while securing funding through late Q1 2027. | ||
 Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call | ||
Inovio Pharmaceuticals Q2 Earnings Call Highlights Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara | ||